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Abstract
A series of synthetic aporphine derivatives structurally related to domesticine and nantenine (ring
A, N6 and ring C truncated analogs), was evaluated in MTS cytotoxicity assays against the human
colon cancer cell lines, HCT-116 and Caco-2. In general, the C1 position of ring A is tolerant of
alkoxy substituents as well as a benzoyl ester functionality. Other modifications evaluated resulted
in a decrease in cytotoxic activity. The most potent compounds identified had IC50 values in the
range 23μM-38μM, comparable to the known cytotoxic agent, etoposide.
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Cancer is the second leading cause of death in developed countries and colon cancer is the
third most common cancer in the world, with prevalence mainly in Western countries.
Despite the fact that many new chemotherapeutic drugs have been developed and many
aggressive treatments are available, cancer death rates continue to rise. 1 Many
chemotherapeutic agents act through cytotoxicity which leads to inhibition of
carcinogenesis. Development of resistance to approved chemotherapy medications as well as
a myriad of side-effects of these compounds in cancer patients, has contributed to the
continued challenge in treating various forms of cancer. Thus, there is a constant search for
new cytotoxic agents that can serve as leads for the development of chemotherapeutics.
Furthermore, the discovery of new cytotoxic agents may afford the opportunity to obtain a
more detailed understanding of the mechanistic underpinnings of this deadly scourge.
Aporphine alkaloids are endowed with a range of biological activities and may well be
considered to be privileged drug discovery scaffolds. For example, naturally occurring and
synthetic aporphines have been investigated as acetylcholinesterase inhibitors, 2-4 CNS
receptor ligands, 5-8 and as antimicrobial 9, antimalarial 10, 11 and antiviral 12, 13 agents. In
addition, there are a number of reports on the cytotoxic activity of some members of this
alkaloid class. 14-16 Prior studies on aporphines as cytotoxic agents have focused exclusively
on naturally-occurring aporphines. The biological targets involved in the cytotoxic activity
of aporphines are yet to be fully elucidated although DNA-mediated and topoisomerase-
related mechanisms appear to play a role in some instances. 17-20 Interpretation of currently
available information with regards to the SAR of these molecules as cytotoxic agents is
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unreliable because of the diversity of assay systems and cell lines employed by various
investigators. To date, no systematic study of the structure-activity relationships (SARs) of
aporphines as cytotoxic agents has been conducted. An understanding of structure-activity
effects is a necessary aspect of any future undertaking to further understand the mechanism
of action of these molecules as well as to capitalize on their therapeutic potential.
Herein, we present results from an SAR evaluation of the cytotoxic activity of a set of
synthetic aporphine derivatives (some of which we have acquired in the process of other
investigations) in the human colon cancer cell lines HCT-116 and Caco-2.
Based on the structural similarity of domesticine (1) and nantenine (2) (Table 1) to other
known cytotoxic aporphines, we initially screened these compounds in HCT-116 and
Caco-2 colon cancer cell lines. In these assays, 1 had moderate activity, (approximately 3
and 4-fold less potent respectively than the benchmark etoposide). However, we were
enthused to find that 2 had potency comparable to that of etoposide in both cell lines. This
suggested that a C1 phenolic group on the aporphine scaffold was detrimental to activity and
we therefore decided to investigate the effect of replacement of this phenolic group with
other moieties. Thus compounds 3-5 were targeted for cytotoxicity studies to aid in
understanding the SAR at this position. In addition, to probe the effects of other structural
changes in ring A and N6 of the aporphine nucleus, compounds 6-12 were evaluated. An
assessment of the requirement for an intact aporphine skeleton was obtained via evaluation
of the seco-ring C analogs 13 and 14.
Compounds 1, 2, 4 and 7-13 were prepared as described by us previously. 2, 7, 8, 21, 22.
Compound 3 was prepared in three steps by alkylation of readily available phenol 108
followed by treatment of the carbamate product with lithium aluminium hydride (Scheme 1)
and alkylation of the secondary amine product thus formed (due to cleavage of the N-
carbamate group). Compound 5 (Scheme 1) was synthesized via lithium aluminium hydride
reduction of 10. This reduction gave predominantly the secondary amine; the crude mixture
was subsequently subjected to reductive amination to yield domesticine (1). Acylation of 1
with benzoic anhydride afforded 5.
Phenol 15, was prepared in a manner analogous to the synthesis of 10, 8 and was brominated
with NBS to give 16 (Scheme 2). In a sequential manner, compound 16 was O-methylated,
the boc group removed by treatment with ZnBr2, and the amine alkylated via reductive
amination to give the bromo-nantenine analog, compound 6. (We also attempted to
synthesize 6 via direct NBS bromination of 2 but found that this method gave poly-
halogenation of the aromatic rings).
Compounds 1-14 were evaluated in MTS assays as described by us 23 with modifications
[24]. Table 2 summarizes the data from this evaluation. Replacement of the C1 hydroxyl
group of domesticine (1) with alkyloxy groups (ie compounds 2-4) resulted in improved
cytotoxicity vs the cell lines tested. The branched alkyl analog 3 was the most potent against
the cell lines evaluated and was approximately 2-fold selective for colon cancer cells vs
normal colon fibroblasts (CCD-18Co).
The n-pentyl analog 4 was slightly less potent than nantenine (2) in the HCT-116 cell line
but was equipotent in the Caco-2 cell line.
Together, these results suggest that C1 alkyl branching results in higher cytotoxicity but also
indicates that increasing n-alkyl chain length is detrimental to activity vs HCT-116 cells.
The benzoyl ester 5 had slightly improved activity as compared to 2 in HCT-116 and Caco-2
cells and was moderately more selective with regards to toxicity in non-tumorigenic human
colon CCD-18Co cells. Addition of a bromine atom to position 3 of nantenine (ie compound
Ponnala et al. Page 2
Bioorg Med Chem Lett. Author manuscript; available in PMC 2012 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
6) decreased cytotoxic activity in all cell lines. Replacement of the N-methyl group of
nantenine (2) with acetyl, ethyl carbamate or methanesulfonyl groups was detrimental to
cytotoxic activity (compounds 7-9 respectively). However, comparison of domesticine (1) to
its N-ethyl carbamate analog 10 revealed no significant difference in cytotoxicity. Although
C1 alkylation gave improved activity in the N-methyl series, this structural change was not
associated with improved activity in the N-ethyl carbamate series of analogs, as comparison
of 10 with 11 and 12 reveals. Cumulatively, the evaluation of 1-12 is indicative of a greater
preference for the N-methyl group of the aporphine skeleton as compared to other N-
protected functionalities in relation to cytotoxic activity. Additionally, the presence of an N-
ethyl carbamate functionality appears to be better tolerated with a C1 hydroxy group than
with a C1 methoxy group on the aporphine skeleton. The ring truncated analogs 13 and 14
had significantly lower activity as compared to 2. This points to a requirement for ring C of
the aporphine nucleus to be intact for cytotoxic activity.
In conclusion, our study has uncovered potent cytotoxic activity of the aporphine alkaloid
nantenine (2), the C1 alkoxy derivative (3) and the C1 benzoate derivative (5). Of these, 3
and 5 exhibit marginally higher selective cytotoxicity vs normal cells. These compounds
have potencies comparable to that of the clinically available anticancer therapeutic drug,
etoposide in vitro. This is the first account of the cytotoxic activity of aporphines in
HCT-116 and Caco-2 human colon cancer cell lines. Our SAR evaluation indicates that the
N-methyl group and the intact aporphine nucleus of 2 are important for its cytotoxic activity.
Interestingly, this study also indicates that 2 may be manipulated via substitution of the C1
methyl group with other alkyl groups without severely compromising cytotoxicity. The
findings herein are relevant to the study of aporphines as potential anticancer drugs and are
also significant in other therapeutic areas (where cytotoxicity of the molecules described
may not be desirable).
The importance of substituents on other portions of the nantenine aporphine core (eg ring D)
remains to be determined. Furthermore, the selectivity vs other cancer cell lines and
mechanism(s) involved in the cytotoxic actions of 2, 3 and 5 are unknown at present. These
are dimensions that we intend to explore in future.
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Scheme 1.
Synthesis of compounds 3 and 5
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Scheme 2.
Synthesis of compound 6
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Table 1
Ring A, N6 and seco-ring C analogs evaluated
Compound # R1 R2 R3
1 H H CH3
2 CH3 H CH3
3 (CH3CH2)2CHCH2 H CH3
4 CH3(CH2)3CH2 H CH3
5 PhCO H CH3
6 CH3 Br CH3
7 CH3 H CH3CO
8 CH3 H CH3CH2OCO
9 CH3 H CH3SO2
10 H H CH3CH2OCO
11 CH3CH2 H CH3CH2OCO
12 PhCH2O H CH3CH2OCO
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Table 2
Cytotoxicity of compounds 1-14 against human colon cancer (HCT-116, Caco-2) and normal colon
(CCD-18Co) cell lines
Compound # IC50 (μM)a
HCT-116 Caco-2 CCD-18Co
1 73.3±4.6 73.5 ±3.2 133.5±3.1
2 38.3±1.6 36.2±2.4 56.5±1.9
3 26.6±1.1 22.8±3.5 50.7±2.0
4 46.3±2.6 35.3±2.4 73.4±2.1
5 25.2±2.2 25.9±1.8 45.1±0.8
6 100.3±2.1 100.7±1.7 180.6±3.5
7 185.7±3.4 159.6±6.4 188.5±2.2
8 81.4±1.2 83.2±3.8 111.6±1.6
9 196.1±3.4 195.8±4.3 n.d.
10 72.7±2.4 71.7±2.8 127.9±5.4
11 73.3±4.6 73.5±3.2 133.5±3.1
12 93.3±4.7 99.8±2.3 109.6±0.6
13 190.9±4.0 191.3±2.5 n.d.
14 195.4±5.7 189.8±5.7 n.d.
etoposide 25.5±2.1 18.6±1.8 44.4±1.8
a
determined at 72 h
n.d.= not determined
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